| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3906008 | Urology | 2006 | 6 Pages |
Abstract
Taxane-based chemotherapy is active before or after mitoxantrone. Although PFS was longer with taxane-based chemotherapy, the total PFS and overall survival were equivalent for both sequences in this retrospective analysis, suggesting that taxane-based chemotherapy retains activity, even if delayed. Although responses were seen with mitoxantrone after taxanes, the median PFS was short, and new agents are needed after taxane-based chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
William K. Oh, Judith Manola, Vladana Babcic, Neesha Harnam, Philip W. Kantoff,